Feature | September 23, 2013

National Registry Report Shows Increase in Radial Stenting, Other CV Trends

September 23, 2013 — Cardiologists are increasingly accessing coronary arteries by way of the wrist rather than the groin to insert life-saving stents into patients with blocked arteries, according to the first broad report of the American College of Cardiology’s clinical data registries published online in the Journal of the American College of Cardiology.

The report, “Cardiovascular Care Facts: A Report from the National Cardiovascular Data Registry ? 2011,” includes data about stents from the CathPCI Registry, the ACC’s national database of hospital records on stenting and angioplasty, as well a wide range of data from the other four ACC National Cardiovascular Data Registries for which comprehensive data from 2011 are available.

The report showed stenting (percutaneous coronary intervention or PCI) performed at the radial access site (the wrist) increased from 2.9 percent of cases in 2009 to 10.9 percent of cases in 2011, while stenting performed at the femoral access site (the groin) decreased from 96.5 percent to 88.8 percent during the same time period. While this approach is new and still being studied, research has shown that radial access can reduce the risk of complications, discomfort and recovery times in some patients. The report suggests that clinicians who perform PCI are becoming more comfortable with this approach and it is becoming more commonly used.

"The data in this report demonstrate the value of national registries in providing an unprecedented and broad perspective on the care and outcomes of patients with cardiovascular disease,” said Frederick Masoudi, M.D., MSP, senior medical officer of the NCDR. “These registries are key tools in understanding and improving care for cardiovascular patients across the United States."

Other top findings from the report outline several successes in heart disease care as well as opportunities for further improving a patient’s treatment and follow-up care experience.

There have been continued improvements in meeting guideline-recommended door-to-balloon (D2B) times of 90 minutes or less for patients with ST-segment elevation myocardial infarction. In the ACTION-GWTG Registry alone, the proportion of patients with D2B times of 90 minutes or less for non-transfer patients increased from 81 percent in 2008 to 94.2 percent in 2011, while among patients who were transferred for percutaneous coronary intervention (PCI) this proportion increased from 18 percent in 2008 to 30.4 percent in 2011.

Findings from the CathPCI Registry show providers are consistently prescribing optimal medical therapy, including aspirin, thienopyridine/P2Y12 inhibitor, lipid lowering agents and beta-blockers, at discharge for PCI patients. Prescription of aspirin and thienopyridine at discharge have remained relatively steady between 96 percent and 98 percent between 2009 and 2011, while prescriptions of lipid lowering agents and beta blockers have increased. Prescription of lipid lowering agents rose from 89.7 percent in 2009 to 92.5 percent in 2011. Beta blocker prescriptions have increased from 83.1 percent to 86.3 percent.

In the PINNACLE Registry, data show there continues to be an opportunity for increased education for patients and clinicians about optimal anticoagulation strategies for stroke prevention in atrial fibrillation, as 57.2 percent of eligible patients with atrial fibrillation were prescribed anticoagulation therapy.

The ICD Registry identifies an opportunity for the use of medical therapy for patients with prior myocardial infarction or left ventricular systolic dysfunction; nearly 25 percent of ICD patients did not receive optimal medical therapy with ACE inhibitors and/or beta blockers at discharge.

PINNACLE Registry data overwhelmingly shows providers regularly recording patient blood pressures (95.1 percent), only a minority (34.5 percent) of providers are taking things a step further and implementing hypertension care plans.

According to CathPCI Registry data, opportunities exist to improve not only adherence to appropriate use criteria in patients without acute coronary syndrome (ACS) but potentially clarify areas of uncertainty. While a little more than half of patients without ACS (52.8 percent) were evaluated appropriately for PCI procedures, 37.3 percent fell into the uncertain category, while nearly 10 percent were inappropriate. In contrast, patients with ACS were appropriately evaluated for PCI procedures 99.1 percent of the time.

For more information: cardiosource.org/ACC

Related Content

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Overlay Init